Norbert G. Riedel

Norbert G. Riedel (senior executive) discloses dealings in 5 companies, chiefly Jazz Pharmaceuticals plc, Cerevel Therapeutics Holdings, Inc. and Aptinyx Inc. Between 1 February 2016 and 5 August 2026, the trades on record add up to 19 filings.

In open-market terms, that means 1 purchase worth €197k on one side and 1 sale worth €163k on the other. Taken together, the purchases exceed the sales by €34k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 9 share grants and 7 option exercises.

The record was last updated on 7 August 2026 with a share grant in Jazz Pharmaceuticals plc. The last insider purchase was made public on 8 December 2021, 1,775 days ago. The median gap between a trade and its publication by SEC (Form 4) is 3 days. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.